---
title: "PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295013801.md"
description: "Pacific Biosciences reported Q2 FY26 revenue of $39 million, a 2% decline, with a widened GAAP net loss of $44.7 million. Gross margin dropped to 32% due to increased costs and lower Revio pricing. While consumables rose 6%, Revio placements reached 20. The company forecasts full-year 2026 revenue between $155-$165 million and launched the SPRQ-Nx system."
datetime: "2026-08-05T20:52:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295013801.md)
  - [en](https://longbridge.com/en/news/295013801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295013801.md)
generator: "portal-rs"
---

# PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million

-   Pacific Biosciences posted Q2 2026 revenue of USD 39 million, down 2% year over year; consumables rose 6% to USD 20.1 million. \* GAAP net loss widened to USD 44.7 million while GAAP net loss per share held at USD 0.14. \* GAAP gross margin fell 5 percentage points to 32% due to higher compute and memory costs, Vega manufacturing transition costs, lower Revio average selling prices. \* Revio system placements climbed to 20, Vega placements slipped to 26; annualized Revio pull-through per system eased to about USD 202,000. \* Forecast 2026 revenue of USD 155 million to USD 165 million; began global SPRQ-Nx rollout, listing whole-genome sequencing at USD 345 per genome. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804409) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PACB.US](https://longbridge.com/en/quote/PACB.US.md)

## Related News & Research

- [AbbVie announces Q4 2026 dividend of R$ 0.37 per unit, payable Nov. 23](https://longbridge.com/en/news/298758281.md)
- [NeuroSense Therapeutics effects 1-for-20 reverse stock split on Sept. 14, 2026](https://longbridge.com/en/news/298501385.md)
- [CANF: Longer-than-expected survival in liver cancer and narrowed net loss mark H1 2026 results](https://longbridge.com/en/news/298966883.md)
- [PHARM: Joenja and RUCONEST fuel growth, with pipeline advances and $375–395M revenue projected for 2026](https://longbridge.com/en/news/299006688.md)
- [Genfit to launch Phase 2a nangibotide proof-of-concept trial in ACLF in Q4 2026](https://longbridge.com/en/news/298943931.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**